Detalles de la búsqueda
1.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J
; 267: 1-11, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37758044
2.
Incretin hormones and type 2 diabetes.
Diabetologia
; 66(10): 1780-1795, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37430117
3.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Circulation
; 145(8): 575-585, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903039
4.
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Cardiovasc Diabetol
; 22(1): 153, 2023 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37381019
5.
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Diabetes Obes Metab
; 25(5): 1361-1371, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36700380
6.
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Cardiovasc Diabetol
; 21(1): 169, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050763
7.
Consensus report: Definition and interpretation of remission in type 2 diabetes.
Diabet Med
; 39(3): e14669, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34460965
8.
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment.
Diabetes Obes Metab
; 24(5): 806-815, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984794
9.
Consensus report: definition and interpretation of remission in type 2 diabetes.
Diabetologia
; 64(11): 2359-2366, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34458934
10.
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Diabetes Obes Metab
; 23 Suppl 3: 5-29, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310013
11.
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
Diabetes Obes Metab
; 23(10): 2344-2353, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34189834
12.
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Diabetes Obes Metab
; 22(4): 699-704, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750601
13.
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(4): 599-611, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31793165
14.
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab
; 22(10): 1886-1891, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32519795
15.
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials.
Diabetes Obes Metab
; 22(9): 1537-1547, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314525
16.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984598
17.
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
Circulation
; 138(25): 2884-2894, 2018 12 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30566004
18.
Effect of portal glucose sensing on incretin hormone secretion in a canine model.
Am J Physiol Endocrinol Metab
; 317(2): E244-E249, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31112407
19.
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists.
Lancet
; 402(10400): 429-431, 2023 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37369233
20.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet
; 392(10160): 2180-2193, 2018 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-30293770